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osting by EAbstract In the last few years, cancer chemotherapy has been successfully employed in the treat-
ment of different types of human tumours. Unfortunately, the optimal clinical usefulness of this
important treatment modality is usually limited secondary to the development of life-threatening
multiple organ toxicity. Cancer chemotherapy may cause these toxic effects by mechanisms not
involved in their anticancer activity that can severely affect the life of patients and represent a direct
cause of death. Several experimental and clinical studies have demonstrated that some important
anticancer drugs interfere with the absorption, synthesis, and excretion of carnitine in non-tumour
tissues, resulting in a secondary carnitine deﬁciency which is reversed by carnitine treatment without
affecting anticancer therapeutic efﬁcacy. Prototypes of anticancer drugs that alter carnitine system
are doxorubicin, cisplatin, carboplatin, oxaliplatin, cyclophosphamide and ifosfamide. Further-
more, cachectic cancer patients are especially at risk for carnitine deﬁciency due to decreased oral
intake and/or increased renal losses. Altered serum and urine carnitine levels have been reported in
cancer patients with various forms of malignant diseases. Recent studies in our laboratory have
demonstrated that carnitine deﬁciency constitute a risk factor and should be viewed as a mechanism
during development of oxazaphosphorines-induced cardiotoxicity in rats. Similarly, inhibition of
gene expression of heart fatty acid-binding protein and organic cation/carnitine transporter in
doxorubicin cardiomyopathic rat model has been reported. In view of these facts and in view of irre-
placeability of these important anticancer drugs, this review aimed to highlight the role of carnitine
depletion and supplementation during development of chemotherapy-induced multiple organ
toxicity.
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carnitine.1. Introduction
1.1. L-carnitine
1.1.1. Historical background
Carnitine, a naturally occurring quaternary ammonium com-
pound, was discovered in muscle extracts in the beginning of
twentieth century by Gulewitsch and Krimberg in Moscow,
Russia (Gulewitsch and Krimberg, 1905) and by Kutscher in
Marburg, Germany (Kutscher, 1905). At that time carnitine
was named from the Latin word carnis which means ﬂesh. In
1927, the chemical structure of carnitine was identiﬁed as b-hy-
droxy-c-trimethyl-amino-butyric acid (Tomita and Senju,
1927). In 1955, Fritz reported that muscle extracts added by
means of rat liver homogenates effected an increase in palmi-
tate oxidation rate (Fritz, 1955). In the same year, Friedman
and Fraenkel (1955) found the reversible transfer of acetyl
groups between carnitine and CoA-SH. In 1962, Bremer
observed that the formed acetyl-carnitine was an effective
supplier of acetyl groups for beta-oxidation in the mitochon-
dria (Bremer, 1962a). Later this year, Bremer (1962b) was the
ﬁrst researcher who described the main physiological function
of carnitine as carrier for the translocation of long-chain fatty
acid from cytoplasmic compartment into mitochondria, where
beta-oxidation enzymes are located for energy production. The
physiological form of carnitine was identiﬁed in 1962 as the L
() isomer, or levocarnitine (Kaneko and Yoshida, 1962). Since
then, the term carnitine has always been referred to as L-carni-
tine. One year later, Bremer (1963) discovered the outer carni-
tine palmitoyl transferase enzyme (CPT I), an essential enzyme
involved in long-chain fatty acid oxidation (Fig. 1).
1.1.2. Carnitine sources and pharmacokinetics
In humans, 75% of the total body carnitine originates from
dietary sources and the remaining 25% from endogenous
synthesis (Tein et al., 1996). Carnitine is synthesized fromthe amino acids lysine and methionine. The rate limiting step
in carnitine biosynthesis is the availability of trimethyllysine
at the intramitochondrial site of trimethyllysine hydroxylase
activity (Rebouche et al., 1986).
L-carnitine is absorbed in the intestine by a combination of
active transport and passive diffusion (Rebouche, 2004).
Mucosal absorption of carnitine is saturated at 2 g (Harper
et al., 1988). Following oral ingestion of 2 g carnitine, the max-
imum concentration is reached at about 3.5 h and then slowly
decreases (Bach et al., 1983). Rebouche and Chenard (1991)
suggested an oral bioavailability of 54–87% depending upon
the quantity ingested. Muscle concentrations of carnitine are
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take of carnitine, but at vastly different rates (Brass, 1992).
Normally, 80% of the total myocardium carnitine uptake
through the circulation and taken up by other tissues through
active sodium dependent organic cation/carnitine transporter
(OCTN2) (Tamai et al., 1998). Carnitine is excreted mainly
in urine; however, a little is lost through the bile. L-carnitine
is highly conservative since 95% of the ﬁltered free carnitine
(FC) is reabsorbed by the renal tubules, and the majority of
the acyl-carnitine (AC) is excreted in urine, thus permitting
excretion of the abnormal metabolites (Tanphaichitr and Lee-
lahagul, 1993).1.1.3. Normal carnitine levels
The total content of carnitine in the human body is about
(16 g) 100 mmol (Bremer, 1983). Muscles contain 98% of that
total amount, while 2% of carnitine is found in the liver and
other tissues, respectively (Engel and Rebouche, 1984). Carni-
tine concentration in the heart is about 4.2 mmol/g tissue,
which is over three times higher than that in the striated mus-
cles (1.26 mmol/g), four times higher than that in the liver
(0.94 mmol/g), and eight times higher than that in the kidney
(0.52 mmol/g) (Steiber et al., 2004). The total carnitine concen-
tration in plasma is usually in the range of 42–85 lmol/L and
that of FC in the range of 35–70 lmol/L (Zdrojkowska-Krol
et al., 1994). Under normal physiological conditions, 80% of
total serum carnitine is FC and 20% is AC with normal AC/
FC ratio of 0.25 (Campos et al., 1993; Bohles et al., 1994). A
free carnitine level in the blood of <20 lmol/L is considered
evidence of carnitine deﬁciency. A ratio of AC/FC more than
0.4 is considered abnormal and represents carnitine insufﬁ-
ciency in which there is insufﬁcient FC relative to increased
metabolic needs (Siliprandi et al., 1990).1.1.4. Carnitine and propionyl-L-carnitine: application to
therapy
L-carnitine and its short-chain derivatives, PLC, have been
successfully used in the treatments and prevention of many dis-
eases including ischemic heart disease (Spagnoli et al., 1982;
Debska-Slizien et al., 1997; Arsenian et al., 1996), arrhythmia
(Cacciatore et al., 1991; Rizzon et al., 1989), peripheral blood
vessel diseases (Pola et al., 1992; Cipolla et al., 1999), primary
carnitine deﬁciencies (Siliprandi et al., 1990), secondary carni-
tine deﬁciencies (Kra¨henbu¨hl and Reichen, 2003; Brass, 2002),
essential treatment for patients undergoing hemodialysis (Mir
et al., 2002; Ahmad et al., 2001), treatment of male infertility
(Matalliotakis et al., 2002), and treatment of beta-thalassemia
(El-Beshlawy et al., 2004, 2005, 2007, 2008).1.1.5. Physiological and biochemical alteration caused by
cancer: role of carnitine
Anorexia, cachexia and malnutrition occur in many chronic
disease states including cancer, heart failure, renal and liver
failure, and autoimmune deﬁciency disease (AIDS). Cachexia
occurs in up to one half of all patients diagnosed with cancer
(Dewys et al., 1980; Toomey et al., 1995). Metabolic altera-
tions caused by cancer cachexia have been attributed to a vari-
ety of interactions between the host and the tumour (Stewart
et al., 1995). One of these metabolic changes that takes place
throughout the body is the reduction in endogenous synthesis
of carnitine. Low serum levels of carnitine in terminal neoplas-tic patients are decreased largely due to the decreased dietary
intake and impaired endogenous synthesis of this substance
(Hoang et al., 2007). These low serum carnitine levels also con-
tribute to the progression of cachexia in cancer patients (Vinci
et al., 2005; Malaguarnera et al., 2006).
1.2. Carnitine and cancer chemotherapy-induced multiple organ
toxicity
1.2.1. Carnitine and doxorubicin-induced cardiomyopathy
Doxorubicin (DOX) was among the ﬁrst anthracycline antibi-
otics to be in clinical use in cancer chemotherapy (Arcamone
et al., 1969). It has a broad-spectrum antitumour activity
against a variety of hematological and solid tumours (Carter,
1975). Unfortunately, the chronic administration of DOX is
associated with the development of dose-dependent and irre-
versible cardiomyopathy, which restricts its usefulness in can-
cer chemotherapy (Goormaghtih and Ruysschaert, 1984;
Kantrowitz and Bristow, 1984; Buzadar et al., 1985). Cardio-
myopathy is the major limiting complication of DOX and af-
fects 30–40% of the patients who receive a cumulative dose
more than 500 mg/m2 (Van Vleet et al., 1980; Lefrak et al.,
1973). Hence, even in responding tumours, it is necessary to
discontinue DOX administration once a cumulative dose of
500 mg/m2 is reached to prevent the onset of irreversible car-
diac damage (Buzadar et al., 1985; Lefrak et al., 1973). In view
of the irreplaceability of DOX in cancer chemotherapy, one of
the research aims being pursued most intensively is the possi-
bility of eliminating its cardiotoxicity or reducing it to an
acceptable level. In this regard, various strategies have been
tried, exempliﬁed by the use of free radical scavengers
(Venkatesan, 1998; Al-Shabanah et al., 1998), iron chelators
(Al-Harbi et al., 1992; Yeung et al., 1992), calcium antagonists
(Rossi et al., 1994], histamine and adrenergic receptor blockers
(Myers and Chabner, 1990).
The effects of L-carnitine and PLC on DOX-induced car-
diomyopathy have extensively been investigated. Several
experimental and clinical studies have reported that DOX in-
duces its cardiomyopathy by inhibition of beta-oxidation of
long-chain fatty acids with the consequent depletion of cardiac
ATP and that L-carnitine supplementation protects the myo-
cardium against this toxicity (De Leonardis et al., 1987;
Abdel-aleem et al., 1997; Sayed-Ahmed et al., 1999a, 2000a;
Strauss et al., 1998; Waldner et al., 2006). In early experiments,
Alberts et al. (1978) investigated the protective effects of carni-
tine against acute (high-dose) and chronic (intermittent, low
dose) DOX toxicity in rat and mice. They found that carnitine
was able to decrease both acute and chronic DOX-linked
lethality in normal rats without decreasing its antineoplastic
activity or raising its bone marrow toxicity. Paterna et al.
(1984) investigated whether L-carnitine could prevent DOX-
induced cardiomyopathies in rabbits by promoting free fatty
acid utilization for energy production and neutralizing long-
chain free fatty acid toxicity occurring after ischemia. The re-
sults showed that L-carnitine reduced the frequency of cardio-
myopathies and increased survival rate. Histopathological
examination of myocardial tissues under light and electron
microscopes revealed a marked decrease in mitochondrial le-
sions. Also, the possible protective effects of L-carnitine
against DOX-induced cardiotoxicity were studied by Neri
et al. (1986). Rat heart slices were incubated with DOX
(14 mg/ml), L-carnitine (600 mg/ml), and DOX plus L-carni-
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intracellular Ca2+ concentration and 14C-leucine incorpora-
tion (an index of protein synthesis). L-carnitine signiﬁcantly re-
duced DOX-induced cardiac metabolic damage. The oxygen
uptake inhibition decreased from 38% to 7%, the decrease
in ATP concentration was reduced from 78% to 27% and
the inhibition of protein synthesis from 11% to 6%. Therefore,
according to Neri et al. (1986), L-carnitine appears to be a use-
ful drug in the prevention of DOX-induced cardiotoxicity. The
protective effects of L-carnitine against DOX-induced cardio-
toxicity in rats were also studied by McFalls et al. (1986).
Cardiomyopathy was induced by weekly intravenous injection
of DOX (2 mg/kg) over a period of 6–7 weeks. Myocardial
Carnitine concentration was not altered by DOX, but plasma
carnitine concentration was increased resembling those of car-
diomyopathies in adults.
Using DOX cardiomyopathic rat model, Shug (1987) de-
signed an experiment to ﬁnd an explanation for the protective
effect of L-carnitine against DOX-induced cardiotoxicity.
After 6 weeks of intravenous administration of DOX, rats
treated without carnitine had a lower ejection fraction and left
ventricular pressure than control or rats treated with DOX
plus L-carnitine. Total carnitine in plasma was signiﬁcantly
higher in rats treated with DOX than control and DOX plus
carnitine. They suggested that the increase in carnitine ester
in plasma of DOX-treated rats was due to DOX-induced inhi-
bition of long-chain fatty acid oxidation.
On the same line, Brady and Brady (1987) reported that
DOX interacts with mitochondrial lipids as a part of its toxic-
ity mechanism and thus inhibits CPT I, an essential enzyme in-
volved in long-chain fatty acid oxidation, in isolated rat liver
mitochondria in the presence of increasing concentrations of
DOX. Based on these observations these authors suggested
that DOX-induced cardiotoxicity may be, at least in part,
due to the inhibition of CPT I. However, this hypothesis was
challenged by Kashﬁ et al. (1990) who reported that the inhi-
bition of CPT I by DOX was unrelated to its cardiotoxicity be-
cause less toxic analogs produced more potent inhibition of
this enzyme. Finally in this regard, Beanlands et al. (1994) have
shown an initial depression of fatty acid oxidation in a work-
ing heart preparation from rats injected chronically with DOX
but again no mechanism for this effect has been ascertained.
Using a neonatal rat model, Strauss et al. (1998) evaluated
the effect of DOX and DOX plus L-carnitine on the induction
of de-novo heat shock protein 25 synthesis. DOX was injected
intravenously at a dose of 9 mg/kg every three days to have a
total dose of 27 mg/kg. L-carnitine was administered intrave-
nously (20 mg/kg) before each subdose of DOX and then in
drinking water (180 mg/kg) daily for 12 weeks. Heat shock
protein of the homogenized heart tissue was determined by
Western blot analysis. Results showed that de-novo synthesis
of heat shock protein was three times more induced in carni-
tine-DOX rats than in DOX ones. The authors suggested that
carnitine may enhance the cell-protecting mechanism based on
an induction of shock protein, and this ﬁrst cellular response
could reduce the severity of DOX-induced-cardiomiopathy.
In isolated cardiac myocytes and mitochondria, Sayed-
Ahmed et al. (1999a) studied the inﬂuence of L-carnitine on
DOX-induced cardiac metabolic damage. The results showed
that, after perfusion of the hearts with 0.5 mM DOX, they
observed a signiﬁcant 70% reduction of palmitate oxidation,
whereas perfusion with L-carnitine increased palmitate oxida-tion by 37%. Addition of L-carnitine to the perfusate 10 min
after perfusion with DOX, reversed 88% of DOX-induced
inhibition of palmitate oxidation. In isolated mitochondria,
DOX had no effect on acyl-CoA synthetase (an enzyme lo-
cated on the outer mitochondrial membrane and responsible
for the activation of long-chain fatty acids into their corre-
sponding acyl-CoA forms) suggesting that DOX has no effect
on the activation step of long-chain fatty acids. However, the
oxidation of palmitoyl-CoA was signiﬁcantly inhibited sug-
gesting that DOX may inhibit CPT I or interfere with L-carni-
tine on binding site on this enzyme. The authors concluded
that the addition of L-carnitine completely reversed the inhibi-
tion of palmitate and palmitoyl-CoA oxidation to control val-
ues. They added that L-carnitine did not interfere with the
antitumour activity of DOX against the growth of Ehrlich
ascites carcinoma cells.
In isolated rat heart myocytes and mitochondria, Sayed-
Ahmed et al. (2000a) studied the effects of different concen-
trations of DOX in absence and presence of PLC on palmi-
toyl-CoA and palmitoyl-carnitine oxidation and on the
activity of CPT 1. The results showed that DOX-induced
concentration-dependent inhibition of substrates oxidation
and inhibition of CPT I and that PLC completely reversed
this inhibition to the control values. They concluded that
DOX induced its cardiotoxicity by inhibition of CPT I and
beta-oxidation of long-chain fatty acids with the consequent
depletion of ATP in cardiac tissues, and that PLC can be
used as a protective agent against DOX-induced cardiotoxic-
ity (Fig. 2).
In DOX cardiomyopathic rat model, Sayed-Ahmed et al.
(2001) have initiated another study to conﬁrm their in vitro
ﬁndings and investigated the protective effects of PLC against
DOX-induced cardiotoxicity. Chronic administration of DOX
(3 mg/kg, I.P) signiﬁcantly increased CK-MB, LDH, GOT and
malondialdehyde and decreased reduced glutathione. Treat-
ment with PLC induced complete reversal of these effects with-
out decreasing the antitumour activity of DOX. In another
study, Sayed-Ahmed et al. (2000b) investigated the effects of
DOX on mRNA expression of heart fatty acid binding protein
(H-FABP) using Northern blot analysis. Results showed that
chronic administration of DOX caused dose-dependent and
cumulative inhibition of H-FABP gene expression and that
daily administration of L-carnitine protected against this effect
in cardiac tissues. Authors concluded that DOX-induces its
cardiotoxicity by inhibition of gene expression of H-FABP
(Fig. 3).
More recently, Sayed-Ahmed et al. (2010) reported that
chronic DOX therapy decreased the expression of H-FABP
and OCTN2 mRNA expression and increased the expression
of apoptotic genes in cardiac tissues that should be viewed as
a mechanism during development of DOX-induced
cardiomyopathy.
On the clinical level, De Leonardis et al. (1985) reported
that DOX therapy is associated with chronic, dose-dependent
and irreversible cardiomyopathy. In their study which in-
volved nine patients, cardiotoxicity occurred in one third of
all patients after cumulative dose of 300 mg/m2. Also, they
investigated whether both acute and chronic DOX cardiotox-
icity can be reversed by L-carnitine. They recommended sys-
temic application of L-carnitine as adjuvant therapy during
DOX treatment to prevent the development of DOX related
cardiomyopathy. In another study, De Leonardis et al. (1987)
Figure 2 Proposed protective mechanism by PLC against DOX-induced cardiomyopathy. CT, carnitin acyl-carnitine translocase; CAT,
carnitine acetyl transferase; CPT I, outer carnitine palmitoyltransferase; CPT II, inner carnitine palmitoyltransferase; PCC, propionyl-
CoA carboxylase; ADR, adriamycin (trade name of DOX); () and (+) indicate inhibition and stimulation, respectively. (Cited from
Sayed-Ahmed et al., 2000a.)
Role of carnitine in cancer chemotherapy-induced multiple organ toxicity 199examined the effects of L-carnitine on DOX and daunorubi-
cin cardiotoxicity in 15 patients with breast and lung cancer.
Their left ventricular performance was assessed by echocar-
diographical determination of the maximum velocities of ﬁbre
shortening and lengthening (VCFmax) as index for the sys-
tolic and diastolic function of the heart. They concluded that
L-carnitine completely reversed DOX and daunorubicin
induced decrease in VCF to the control values even after
six therapeutic cycles.The role of L-carnitine in DOX-induced cardiotoxicity was
also studied by Mortensen et al. (1986) who examined 38 pa-
tients with solid tumours and hematological cancer by means
of ECG, chest X-ray and echocardiography. They suggested
the application of cardioprotective substances such as L-carni-
tine in order to reduce the severe DOX cardiotoxicity, pointing
out that their use might be the beginning of a new era of pre-
vention. Waldner et al. (2006) examined the effects of L-carni-
tine with a view to reducing cardiotoxicity of DOX-containing
Figure 3 Inhibition of H-FABP mRNA expression in the heart as a novel mechanism for DOX-induced cardiotoxicity and for L-
carnitine mediated protection against this effect. FFA: free fatty acid; CT: carnitine/acyl-carnitine translocase; FA-CoA: fatty acyl-CoA;
CAT: carnitine acetyl transferase; FA-Carnitine: fatty acyl-carnitine; H-FABP: heart-type fatty acid binding protein; CPT I: outer
carnitine palmitoyl transferase; CPT II: inner carnitine palmitoyl transferase; OCTN2: organic cation/carnitine transporter; () and (+)
indicate inhibition and stimulation, respectively. (Cited from Sayed-Ahmed et al. (2000b).)
200 M.M. Sayed-Ahmedchemotherapy in 20 patients with Non-Hodgkin lymphoma.
Patients were scheduled to receive 3 g L-carnitine before each
chemotherapy cycle, followed by 1 g L-carnitine/day during
the following 21 days. Carnitine-treated patients showed a rise
in plasma carnitine which led to an increase of relative mRNA
levels from CPT 1 and OCTN2. They concluded that biochem-
ical and molecular analyses indicated a stimulation of oxida-
tive metabolism in white blood cells through carnitine uptake.
Yaris et al. (2002) examined relationship between serum
carnitine levels and cardiac dysfunction during treatment with
DOX. Fifteen patients were evaluated prospectively. Measure-
ment of carnitine levels and evaluation of cardiac function
were performed prior to treatment, and after cumulative doses
of 180 and 300 mg/m2 in 15 patients and 20 healthy children
served as control group to obtain reference values. They con-
cluded that there was a trend towards decreasing serum carni-
tine levels and increasing cardiac dysfunction with increasing
cumulative doses of DOX. In contrast, Yoon et al. (2003) have
reported that DOX caused signiﬁcant elevations of plasma free
acyl and total carnitine.
1.2.2. Carnitine and doxorubicin-induced hepatorenal
dysfunction
Doxorubicin-induced hyperlipemia in rats was investigated by
Bizzi et al. (1983). Results showed that massive hyperlipemia
occurred 14–21 days after a single dose of DOX (7.5 mg/kg
intravenous). Lipid synthesis and secretion were decreased.
Mitochondrial oxidation of long-chain fatty acids was mark-
edly reduced in kidney. Lipoprotein lipase activity was reducedin adipose tissue. They suggested that DOX-related hyperlipe-
mia is due to reduced lipid storage and utilization and that
Carnitine supplementation did not counteract hyperlipemia
and proteinuria after DOX. Moreover, nephrotoxicity and oxi-
dative stress induced by DOX in rats were investigated by
Boonsanit et al. (2006) who found that L-carnitine can prevent
renal impairment functionally, biochemically and histopatho-
logically with a corresponding reduction of oxidative stress.
Zeidan et al. (2002) evaluated the heart and liver responses
after DOX toxic aggression, with and without exogenous L-
carnitine protection. Results showed that DOX-induced
long-term cardiac subcellular pathology included loss, disrup-
tion and disassembly of myoﬁbrils, and mitochondrial swelling
and condensation. On the other hand, the DOX-induced sub-
cellular hepatic alterations consisted of polymorphic mito-
chondria, cytoplasmic vacuolization and accumulation of
lipid droplets. However, these alterations were of less severity
in carnitine-treated group in both heart and liver, suggesting
that carnitine could be used as a possible hepatoprotector
agent against DOX-induced toxicity.
1.2.3. Carnitine and cisplatin-induced nephrotoxicity
Cisplatin, cis-diamminedichloroplatinum II (CDDP), is an
inorganic platinum compound with a broad-spectrum antineo-
plastic activity against various types of animal and human tu-
mours (Loehrer and Einhom, 1984). Unfortunately, the
optimal usefulness of CDDP as an important anticancer drug
is usually limited secondary to its dose related nephrotoxicity
(Lieberthal et al., 1996). It is well known that CDDP-induced
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cancer chemotherapy (Lieberthal et al., 1996). Several mecha-
nisms have been suggested, among which oxidative stress is the
best studied mechanism. Oxidative stress is caused mainly by
increasing lipid peroxidation and depletion of glutathione,
which, in turn, induces apoptosis of renal proximal tubule cells
and consequent kidney dysfunction (Zhang and Lindup, 1993;
Kuhlmann et al., 1997). Furthermore, owing to the toxic effect
of CDDP on renal tubules, CDDP inhibits speciﬁc membrane
transport systems, with a consequent increase in the excretion
of a number of essential endogenous substances, including L-
carnitine and amino acids (Seguro et al., 1989; Heuberger
et al., 1998; Chang et al., 2002).
Kidney plays an important role in keeping the homeostasis
of carnitine by conserving 95% of the ﬁltered carnitine (Man-
cinelli et al., 1995). In kidney, carnitine is reabsorbed efﬁciently
by a speciﬁc sodium-dependent transport system located in the
proximal tubule (Stieger et al., 1995). It is well documented
that renal carnitine excretion increases dramatically in patients
with proximal tubular damage such as Fanconi Syndrome
(Bernardini et al., 1985; Steinmann et al., 1987). Heuberger
et al. (1998) examined the effect of CDDP on plasma concen-
trations and urinary excretion of carnitine in ten patients with
different malignancies treated with CDDP-based chemother-
apy. The results showed that during treatment with CDDP,
the total plasma carnitine concentration increased by approx-
imately 30% and normalized 7 days after stopping therapy.
Urinary excretion of total carnitine increased by a factor of
10 during CDDP administration and also normalized 7 days
after cessation of chemotherapy. This increase was due to
excretion of both free carnitine and acyl-carnitine that aver-
aged approximately 1 mmol carnitine per day. Similarly, uri-
nary clearance of total carnitine was increased during
therapy with CDDP by a factor of approximately 8 and re-
turned to normal 7 days after chemotherapy. They concluded
that treatment with CDDP is associated with a tenfold increase
in renal carnitine excretion, most likely due to inhibition of
carnitine reabsorption by the proximal tubule of the nephron.
Well-nourished patients support this loss of carnitine even
after repeated cycles of chemotherapy without developing hyp-
ocarnitinaemia. However, cachectic patients with decreased
dietary carnitine uptake may develop carnitine deﬁciency when
treated repeatedly with chemotherapies including CDDP.
Mancinelli et al. (2007) evaluated the effect of carboplatin-
based chemotherapy on plasma concentrations and urinary
excretion of L-carnitine and its main ester, ALC, in 11 cancer
patients on carboplatin therapy (1 h intravenous infusion for
1 h) in combination with docetaxel, paclitaxel or vinorelbine.
Before carboplatin therapy, the mean ± SD plasma concen-
trations of L-carnitine and ALC were 47.8 ± 10.9 and
7.04 ± 1.04 nmol/ml, respectively, and remained constant
throughout the entire study period. In contrast, urinary excre-
tion of L-carnitine and ALC increased signiﬁcantly during the
chemotherapy from 115 ± 105 to 480 ± 348 lmol/day and
from 41 ± 41 to 89 ± 52 lmol/day (P< 0.05) for L-carnitine
and ALC, respectively, subsequently reverting to normal
6 days after the end of chemotherapy. Similarly, the renal
clearance of L-carnitine and ALC increased substantially dur-
ing chemotherapy from 1.67 ± 1.43 to 9.05 ± 9.52 ml/min
and from 4.02 ± 4.51 to 7.97 ± 5.05 ml/min for LC and
ALC, respectively, reverting to normal 6 days after the end
of chemotherapy. Plasma concentrations and urinary excretionof glucose, phosphate and urea nitrogen and creatinine clear-
ance were not affected by carboplatin therapy, indicating no
impaired kidney function. They concluded that treatment with
carboplatin was associated with a marked urinary loss of LC
and ALC, most likely due to the inhibition of carnitine reab-
sorption in the kidney.
Recently, Haschke et al. (2010) investigated whether oxa-
liplatin alters plasma and urine carnitine level as the case with
CDDP and carboplatin, and if so, what are the possible mech-
anisms. A total of 22 patients treated either with a single dose
of cisplatin, carboplatin or oxaliplatin. Carnitine and kidney
function parameters were determined in plasma and urine.
Also, inhibition of OCTN2 in L6 cells (overexpressing
OCTN2) and mRNA expression of OCTN2 in 293-EBNA
cells were assessed. Results showed that renal excretion of free
and short-chain acyl-carnitine increased 4–10 times during
treatment and normalized 1 week after administration of cis-
platin, carboplatin or oxaliplatin. Renal excretions of al-
pha1-microglobulin and other proximal tubular markers
were also increased, compatible with a proximal tubular de-
fect. Direct inhibition of OCTN2 expressed in L6 cells by cis-
platin, oxaliplatin or platinum could not be demonstrated, and
experiments using urine from patients treated with CDDP
inhibited OCTN2 activity not more than the expected from
the carnitine content in the respective urine sample. CDDP
was associated with a time-and concentration-dependent de-
crease of OCTN2 mRNA and protein expression in 293-
EBNA cells. They concluded that all platinum derivatives
investigated are associated with renal tubular damage in hu-
mans without signiﬁcantly affecting glomerular function. The
rapid onset and complete reversibility of this effect favor a
functional mechanism such as impaired expression of OCTN2
in proximal tubular cells.
One mechanism contributing to cancer-related fatigue in-
volves the decrease in ATP synthesis secondary to carnitine
deﬁciency. Hockenberry et al. (2009) examined fatigue and car-
nitine levels in 76 patients before and 1 week after ifosfamide
(IFO), CDDP, or DOX chemotherapy. Results showed that
there was a signiﬁcant increase in free and total carnitine levels
after treatment for patients receiving doxorubicin than patients
receiving cisplatin or ifosfamide. Increased fatigue and de-
creased carnitine were signiﬁcantly correlated a week after che-
motherapy in children/adolescents who had received prior
chemotherapy. They concluded that decreased carnitine and
increased fatigue occurred after 1–2 courses of chemotherapy
which provides support for an inverse relationship between
carnitine and fatigue in children/adolescents with cancer.
On the experimental level, Sayed-Ahmed et al. (1999b) were
the ﬁrst to report that L-carnitine has a considerable protective
effect against CDDP-induced nephrotoxicity in rats. Chang
et al. (2002) demonstrated that L-carnitine strongly inhibited
CDDP-induced mitochondrial dysfunction and DNA injury, li-
pid peroxidation, and apoptosis of epithelial cells in the kidney
and small intestine without interfering with the tumoricidal ac-
tion of CDDP against cancer cells inoculated in the peritoneal
cavity. They concluded that L-carnitine may have therapeutic
potential for inhibiting the side effects of CDDP and other
anticancer agents in the kidney and small intestine. Two years
later, Sayed-Ahmed et al. (2004) reported the progression of
CDDP-induced nephrotoxicity in carnitine-depleted rat model.
They concluded that carnitine deﬁciency is a risk factor and
should be viewed as a mechanism in CDDP-related kidney
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CDDP-induced nephrotoxicity. Moreover, Aleisa et al. (2007)
reported that carnitine supplementation, using PLC, showed
complete reversal of cisplatin-induced carnitine deﬁciency and
energy starvation in rat kidney tissues. Consistent with these
ﬁndings, moreover, Arafa (2008) reported that carnitine
deﬁciency, whether being a causative clue or a sequela, might
represent a risk factor in carboplatin nephropathy.
Renal interstitial ﬁbrosis is a major complication of CDDP
treatment, due to the increased accumulation of extracellular
matrix (ECM) proteins that remodeling is important for the
development of normal tissues; indeed, its malfunction might
play a role in the etiology of various diseases. In this regard
and recently, Martinez et al. (2009) examined the localization
and expression of matrix metalloproteinase-9 (MMP-9) and
tissue inhibitor metalloproteinase-3 (TIMP-3) in rat kidney,
7, 10 and 15 days after treatment with CDDP, with and with-
out L-carnitine. Results showed that CDDP increased expres-
sion of MMP-9 and decreased expression of TIMP-3 in
glomerular and tubular sections. Pre-treatment with L-carni-
tine induced an important reduction in MMP-9 expression
and increase in TIMP-3. They concluded that matrix remodel-
ing by MMP-9 and TIMP-3, in the later stages, can play an
important role in the development of glomerular sclerosis
and interstitial ﬁbrosis after CDDP treatment. Also, they pos-
tulated that L-carnitine protects from CDDP injury, by mod-
ulating the relationship between MMP-9 and TIMP-3.
Tufekci et al. (2009) investigated, on mechanism-based, the
protective effects of ALC on CDDP-induced nephrotoxicity in
rats. They concluded that antioxidative, antiapoptotic and
anti-inﬂammatory properties of ALC were supported by the
ﬁndings that this agent improves kidney function tests and
has the effects of tissue protection and inhibition of apoptosis
in cisplatin-induced nephrotoxicity. Altun et al. (2010) exam-
ined the effects of ALC on CDDP-induced cytotoxicity and
oxidative stress in neuroblastoma cells. Results showed that
ALC effectively inhibited the increase in CDDP-induced oxi-
dized glutathione and lipid peroxidation formation in neuro-
blastoma cells.
1.2.4. Carnitine and cisplatin-induced neurotoxicity
In addition to bone marrow suppression and renal toxicity,
neurotoxicity is a commonly occurring side effect of widely
used chemotherapeutic agents like taxanes, cisplatin and vin-
ca alkaloids. Neurotoxicity can cause antitumor therapy dis-
continuation or dose regimen modiﬁcation. Pisano et al.
(2003) tested the hypothesis that ALC may have a protective
role on cisplatin and paclitaxel-induced neuropathy in rats.
Their results indicated that ALC is a speciﬁc protective
agent for chemotherapy-induced neuropathy after cisplatin
or paclitaxel treatment without showing any interference
with the antitumor activity of the drugs. Bianchi et al.
(2005) investigated the effect of oral ALC (1 g two times
daily) for 8 weeks in 25 patients with neuropathy grade 3
during paclitaxel or CDDP therapy, or grade 2 persisting
for at least three months after discontinuing the drugs. They
strongly recommend ALC testing in preventing progression
or reverting symptoms during CDDP, paclitaxel and neuro-
toxic chemotherapy. Maestri et al. (2005) examined the ef-
fect of ALC in reversing peripheral neuropathy in patients
with chemotherapy-induced peripheral neuropathy. A total
of 27 patients received at least one cisplatin (n= 5) orone paclitaxel (n= 11)-based regimen, or a combination of
both (n= 11). Patients with chemotherapy-induced periphe-
ral neuropathy were treated with ALC 1 g by intravenous
infusion over 1–2 h for at least 10 days. They concluded that
ALC seems to be an effective and well-tolerated agent for
the treatment of chemotherapy-induced peripheral neuropa-
thy. Graziano et al. (2002) have demonstrated that oral car-
nitine supplementation (4 gm/day) for 7 days to cancer
patients receiving either CDDP-based in 44 patients or
IFo-based in 6 patients was effective in alleviating chemo-
therapy-induced fatigue and normalizing serum carnitine
levels.
1.2.5. Carnitine and cisplatin-induced cardiomyopathy
Using an animal model of carnitine deﬁciency, Al-Majed et al.
(2006) examined whether carnitine deﬁciency, secondary to
CDDP-induced nephrotoxicity, could contribute or enhance
CDDP-induced cardiac dysfunction. They concluded, for the
ﬁrst time, that carnitine deﬁciency and oxidative stress are risk
factors and should be viewed as mechanisms during develop-
ment of CDDP-related cardiomyopathy and that carnitine
supplementation, using PLC, prevents the progression of
CDDP-induced cardiotoxicity.
1.2.6. Carnitine and cisplatin-induced hepatotoxicity
In carnitine-depleted rat model, Al-Majed (2007) investigated
whether or not carnitine deﬁciency is a risk factor and could
contribute to CDDP-induced liver toxicity, and if so, whether
carnitine supplementation using PLC could offer protection
against this toxicity. The author concluded that oxidative
stress is not the main cause of CDDP-related hepatotoxicity
but rather carnitine deﬁciency provokes CDDP-induced hepa-
totoxicity and that carnitine supplementation prevents the
development of CDDP-induced liver injury.
1.2.7. Carnitine and carboplatin-induced bone marrow toxicity
Abd-Allah et al. (2005) have initiated an in vitro study utilizing
bone marrow cell cultures and reported that L-carnitine is
effective not only in protecting against carboplatin-induced
kidney damage but it is also effective in protecting against car-
boplatin-induced myelosuppression.
1.2.8. Carnitine and oxazaphosphorines-induced organs toxicity
Cyclophosphamide (CP) and ifosfamide (IFO) are alkylating
oxazaphosphorine agents that are commonly used in most can-
cer chemotherapy and immunosuppressive protocols (Murphy
et al., 1986; Preiss and Baumann, 2001). Unfortunately, the
optimal clinical usefulness of these drugs is severely limited
by a high incidence of urotoxicity, cardiotoxicity and nephro-
toxicity (Brock et al., 1982; Colvin, 1999; Ludeman, 1999; Luo
et al., 2008). The metabolic pathway of oxazaphosphorines
leads to formation of chloroacetyl-CoA, with subsequent
depletion of the CoA-SH levels. Carnitine is known to detoxify
excess amounts of CoA-bound moieties with formation of
acylcarnitines, which are excreted and detected in urine after
IFO therapy resulting in secondary carnitine deﬁciency (Visa-
rius et al., 1999; Dubourg et al., 2001). Another major metab-
olite of oxazaphosphorines is thiodiglycolic which when
administered to rats, inhibits the carnitine-dependent oxida-
tion of palmitic acid by 55%, but does not affect the oxidation
of carnitine-independent substrates. Additionally, thiodigly-
colic acid inhibited oxidation of palmitic acid but not palmi-
Role of carnitine in cancer chemotherapy-induced multiple organ toxicity 203toyl-L-carnitine in isolated rat liver mitochondria, indicating
that it either sequesters carnitine or inhibits CPT I (Hofmann
et al., 1991).
Marthaler et al. (1999) were the ﬁrst to measure urinary
excretion of carnitine in 5 patients with advanced soft tissue
sarcoma during a continuous infusion of IFO over 5 days at
a dose of 2.8–3.2 g/m2 per day. The results showed that the
excretion of both free and total carnitine signiﬁcantly increased
on the ﬁrst day of chemotherapy and then gradually decreased.
The average loss of carnitine during a chemotherapy cycle
amounted to 8.5 mmol (10% of total carnitine stores). They
concluded that formation and excretion of carnitine esters
and the metabolites of IFO and/or a decreased renal tubular
reabsorption could account for this marked loss, which might
lead to symptomatic carnitine deﬁciency after several chemo-
therapy cycles.
Using carnitine-depleted rat model, recent studies (Dar-
weesh, 2009; Fatani et al., 2010), investigated whether carnitine
deﬁciency plays a role and should be viewed as a mechanism
during development of CP-induced cardiomyopathy as well
as exploring on mechanism-based if carnitine supplementation
using PLC could offer protection against this toxicity. They
concluded that carnitine deﬁciency is a risk factor and should
be viewed as a mechanism in CP-related cardiomyopathy, ser-
um and urine carnitine levels should be monitored and viewed
as indices of CP-induced multiple organ toxicity and that carni-
tine supplementation, using PLC, prevents the development of
CP-induced cardiotoxicity. On the same track, Darweesh
(2009) investigated the effects of the standard IFO-induced
Fanconi Syndrome regimen on serum, urine and cardiac carni-
tine levels in normal and carnitine-depleted rats and its rela-
tionship to IFO-induced cardiotoxicity. They concluded that
using IFO at the standard doses that induce Fanconi Syndrome
is associated with increased urinary losses of carnitine. The
authors added that this carnitine deﬁciency, secondary to Fan-
coni Syndrome, provokes IFO-related cardiotoxicity and that
carnitine supplementation, using PLC, ameliorates the severity
of IFO-induced multiple organ toxicity.
1.2.9. Carnitine and bleomycin-induced pulmonary ﬁbrosis
The optimal clinical usefulness of bleomycin as an important
antineoplastic drug is usually limited due to the development
of dose and time-dependent interstitial pneumonitis and pul-
monary ﬁbrosis. In bleomycin-induced lung ﬁbrosis rat model,
(Daba et al., 2002) have demonstrated that L-carnitine
(500 mg/kg) decreased bleomycin-induced elevations of serum
tumour necrosis-alpha (TNF-a), lipid peroxide level in lung
tissues and enhanced responsiveness of pulmonary arterial
rings to 5-HT. Moreover, Sayed-Ahmed et al. (2004) reported
that acetyl-carnitine attenuated bleomycin-induced acute lung
injury, which was attributed to its free radical scavenging
properties with the consequent improvement in mitochondrial
function and ATP production.
2. Conclusion
Depending on the data presented in this review on the experi-
mental and clinical levels, L-carnitine should be viewed as a
leading candidate and must be given along with doxorubicin,
cisplatin, carboplatin, oxaliplatin, cyclophosphamide and
ifosfamide to block their multiple organ toxicities and to per-
mit larger doses of these anticancer drugs to be administered,thereby killing more cancer cells and increasing the chances of
patient survival.References
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